Incidence and prognostic value of multiple gene promoter methylations in gliomas

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 349-356

  Zhang, Longzhou ^a   Wang, Maode ^a   Wang, Wei ^a   Mo, Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarker; Glioma; Promoter methylation; Serum

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DAPK 1 GENE; DNA METHYLATION; FEMALE; GENE MUTATION; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PARP 1 GENE; PREDICTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QUANTITATIVE STUDY; SHP 1 GENE; TIMP 3 GENE;

ADULT; AGED; BRAIN NEOPLASMS; DEATH-ASSOCIATED PROTEIN KINASES; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GLIOMA; HUMANS; INCIDENCE; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; TISSUE INHIBITOR OF METALLOPROTEINASE-3; YOUNG ADULT;

EID: 84893674946     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1301-5     Document Type: Article

References (50)

1. Tsou JA, Hagen JA, Carpenter CL et al (2002) DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21:5450-5461
2. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128(4):683-692
3. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16(4):168-174
4. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428
5. Das PM, Singal R (2004) DNA methylation and cancer. J Clin Oncol 22:4632-4642
6. Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4:707-717
7. Lo KW, Kwong J, Hui AB et al (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61:3877-3881
8. Sato F, Meltzer SJ (2006) CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106:483-493
9. Xing EP, Nie Y, Wang LD et al (1999) Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 20:77-84
10. Nie Y, Liao J, Zhao X et al (2002) Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 23:1713-1720
11. Ramirez JL, Taron M, Balana C et al (2003) Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst 48:34-41
12. Chan KC, Lo YM (2007) Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer 96(5):681-685
13. Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225-3229
14. Schwarzenbach H, Chun FK, Muller I et al (2008) Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer. BJU Int 102(2):253-258
15. Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102(45):16368-16373
16. Fujiwara K, Fujimoto N, Tabata M et al (2005) Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11(3):1219-1225
17. Altman DG, Lausen B, Sauerbrei B et al (1994) Dangers of using 'Optimal' cutpoints in the valuation of prognostic factors. J Natl Cancer Inst 86:829-835
18. Miller R, Siegmund D (1982) Maximally selected Chi square statistics. Biometrics 38(4):1011-1016
19. Chan KC, Lo YM (2007) Circulating tumor-derived nucleic acids in cancer patients: potential applications as tumour makers. Br J Cancer 96:681-685
20. Skvortsova TE, Rykova EY, Tamkovich SN et al (2006) Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumor-related gene methylation. Br J Cancer 94:1492-1495
21. Lavon I, Refael M, Zelikovitch B et al (2010) Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-oncology 12:173-180
22. Paci M, Bellesia E, Maramotti S et al (2009) Circulating plasma DNA as diagnostic biomarker in non-cell lung cancer. Lung Cancer 64:92-97
23. Amirian E, Liu Y, Michael E (2010) Genetic variants in inflammation pathway genes and asthma in glioma susceptibility. Neuro Oncol 12:444-452
24. Okezie O, Kanu BH (2009) Glioblastoma multiforme oncogenomics and signaling pathways. Clin Med Oncol 3:39-52
25. Ogino H, Nozaki T, Gunji A et al (2007) Loss of PARP-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells. BMC Genomics 8:41
26. Pachkowski BF, Tano K, Afonin V et al (2009) Cells deficient in PARP-1 shows an accelerated accumulation of DNA single strand breaks, but not AP sites, over the PARP-1 proficient cells exposed to MMS. Mutat Res 671:93-99. doi: 10.1016/j.mrfmmm.2009.09.006
27. Joseph A, Soto D, Deng C (2006) PARP-1 inhibitors: are they the long sought genetically specific drugs for BRCA1/2 associated breast cancers? Int J Med Sci 3:117-123
28. Davis JD, Lin SY (2011) DNA damage and breast cancer. World J Clin Oncol 10:329-338
29. Wu C, Sun M, Liu L (2003) The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306:1-12
30. Oka T, Yoshino T, Hayashi K et al (2001) Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 159:1495-1505
31. Kim JH, Choi YD, Lee JS et al (2010) Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol 116:99-104
32. Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71:713-721
33. Hoffmann AC, Vallbohmer D, Prenzel K et al (2009) Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol 135:1231-1237
34. Hu SL, Kong XY, Cheng ZD et al (2010) Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 96:726-733
35. Wang Y, Zhang D, Zheng W et al (2008) Multiple gene methylation of nonsmall cell lung cancers evaluated with 3-dimensional microarray. Cancer 112:1325-1336
36. Ebert MP, Mooney SH, Tonnes-Priddy L et al (2005) Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia 7:771-778
37. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
38. Kitange GJ, Carlson BL, Mladek AC et al (2009) Evaluation of MGMT Promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol 92:23-31
39. 6-methylguanine-DNA methytranseferase mRNA and its significance as indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 69:420-425
40. Kim YH, Nobusawa S, Mittelbronn M et al (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177:2708-2714
41. Sanoson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154
42. Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002-6007
43. Juratli TA, Kirsch M, Roble K et al (2012) IDH1 mutations as an early and consistent marker in low-grade astrocytomas WHO grade and their consecutive secondary high-grade gliomas. J Neurooncol 108:403-410. doi: 10.1007/s11060-012-0844-1
44. Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-773
45. Wojdacz TK (2007) Dobrovic A (2007) Methylation sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 35:e41
46. Liu W, Guan M, Bing S et al (2010) Rapid determination of AKAP12 promoter methylationn levels in peripheral blood using methylation-sensitive high resolution melting (MS-HRM) analysis: application in colorectal cancer. Clin Chim Acta 411:940-946
47. Smart A, Martin P (2006) The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Stud Hist Philos Biol Biomed Sci 37:589-601
48. Bremnes RM, Sirera R, Camps C (2005) Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 49(1):1-12
49. Sunami E, Shinozaki M, Higano CS et al (2009) Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem 55(3):559-567
50. Catarino R, Coelho A, Medeiros R (2012) Circulating DNA and NSCLC: old findings with new perspectives. J Thorac Dis 4(5): 442-443